Severe Acute Respiratory Syndrome (SARS) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family. Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS.

The SARS – drugs in development research report provides a comprehensive overview on the therapeutics under development for SARS, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for SARS and features dormant and discontinued projects.

Key Targets in the SARS Pipeline Drugs Market

The key targets in the SARS pipeline drugs market are 2019 Novel corona Virus Spike Glycoprotein, Human SARS coronavirus Spike Glycoprotein, Middle East Respiratory Syndrome Coronavirus S Protein, Cytosolic Phospholipase A2, 2′-5′ Oligoadenylate Synthetase, 3C Like Proteinase, Cathepsin L1, Coagulation Factor XII, and Envelope Small Membrane Protein, Fatty Acid Synthase.

SARS Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key MoA in the SARS Pipeline Drugs Market

The key mechanisms of action in the SARS pipeline drugs market are 2019 Novel corona Virus Spike Glycoprotein Inhibitor, Human SARS coronavirus Spike Glycoprotein Inhibitor, Middle East Respiratory Syndrome Coronavirus S Protein Inhibitor, Cytosolic Phospholipase A2 Inhibitor, 2′-5′ Oligoadenylate Synthetase Activator, 3C Like Proteinase Inhibitor, Cathepsin L1 Inhibitor, Coagulation Factor XII Inhibitor, Envelope Small Membrane Protein Inhibitor, Fatty Acid Synthase Inhibitor.

SARS Pipeline Drugs Market, by MoA

To get more insights on key MoA, download a free sample report

SARS Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the SARS pipeline drugs market are Intravenous, Nasal, Oral, Inhalational, Intradermal, Intramuscular, Subcutaneous, Intratumor, Ophthalmic, Parenteral, and Vaginal.

SARS Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the SARS Pipeline Drugs Market

The key molecule types in the SARS pipeline drugs market are Small Molecule, Subunit Vaccine, Monoclonal Antibody, Synthetic Peptide, Fusion Protein, Oligonucleotide, Recombinant Vector Vaccine, Antibody, Biologic, Cell Therapy among others.

SARS Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the SARS Pipeline Drugs Market

The major companies in the SARS pipeline drugs market are Adagio Therapeutics Inc, Halo Therapeutics Ltd, AIkido Pharma Inc, AlphaVax Inc, Amide Technologies Inc, Autoimmune Technologies LLC, Biotron Ltd, BioVaxys Technology Corp, Calder Biosciences Inc, and Cidara Therapeutics Inc among others.

SARS Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

SARS Pipeline Drugs Market Overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of SARS
• The pipeline guide reviews pipeline therapeutics for SARS by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in SARS therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates SARS therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews the latest news related to pipeline therapeutics for SARS

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for SARS
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding SARS pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.